Cabinet IV · Recurring Questions
Plain Answers from the Trial Record
The questions that recur in the inbox and the queries — answered from the same trial record that the rest of the cabinet draws on, with citations attached.
Inscribed · May MMXXVI · Cabinet IV
What is tirzepatide?
Tirzepatide is a thirty-nine-amino-acid synthetic peptide that activates two receptors at once — the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Its molecular formula is C225H348N48O68, its molecular weight is 4810.52 Da, and its CAS number is 2023788-19-2. It is administered subcutaneously once weekly and is approved by the United States Food and Drug Administration for type 2 diabetes and for chronic weight management; it has also met primary endpoints in trials for heart failure with preserved ejection fraction, obstructive sleep apnoea, and metabolic dysfunction-associated steatohepatitis[3][6][7][8].
How does tirzepatide work as a dual GIP and GLP-1 receptor agonist?
Tirzepatide engages both incretin receptors but unequally. Its affinity at the GIP receptor approximates that of native GIP; its affinity at the GLP-1 receptor is approximately five-fold weaker than native GLP-1, and at GLP-1R the molecule's signalling is biased — it favours cyclic-AMP generation over beta-arrestin recruitment, which reduces receptor internalisation and sustains downstream signalling[4]. Downstream the molecule enhances glucose-dependent insulin secretion from pancreatic β-cells, suppresses glucagon from α-cells, slows gastric emptying, and acts on hypothalamic feeding circuits to reduce appetite. Effects on adipose-tissue lipid handling and insulin sensitivity appear to operate beyond what weight loss alone would predict.
What is the half-life of tirzepatide?
The mean elimination half-life of tirzepatide is approximately five days, or roughly one hundred and twenty hours, in humans following subcutaneous administration. Absolute subcutaneous bioavailability is approximately eighty percent and albumin binding is approximately ninety-nine percent. Steady-state is reached at approximately four weeks of once-weekly dosing, with a 1.6-fold accumulation factor[5]. The extended half-life is driven primarily by the C20 fatty diacid moiety, which produces the high albumin binding, and is the load-bearing reason once-weekly dosing is feasible.
What does the SURMOUNT-1 trial show about tirzepatide and weight loss?
SURMOUNT-1 enrolled adults with obesity or overweight and at least one weight-related comorbidity (excluding type 2 diabetes) and reported mean body-weight reductions of sixteen percent, 21.4 percent, and 22.5 percent at five, ten, and fifteen milligrams subcutaneous once weekly, against 2.4 percent on placebo, at seventy-two weeks. Between eighty-nine and ninety-six percent of treated participants achieved at least five-percent body-weight reduction, compared with twenty-eight percent on placebo[3]. A 176-week post-hoc analysis subsequently observed reductions of 4.6 to 9.2 percent in ten-year predicted atherosclerotic-cardiovascular-disease risk, dose-dependently, against an increase in the placebo arm[15].
How does tirzepatide compare to semaglutide in clinical research?
Two head-to-head trials are the relevant record. SURPASS-2 placed the three approved doses of tirzepatide against once-weekly semaglutide one milligram in adults with type 2 diabetes on metformin; tirzepatide was noninferior to semaglutide at five milligrams and superior at ten and fifteen milligrams on both HbA1c and weight outcomes, and the fifteen-milligram arm produced nearly twice the weight loss[2]. SURMOUNT-5, published in 2025, placed tirzepatide directly against semaglutide 2.4 milligrams in adults with obesity without diabetes; mean weight reduction at seventy-two weeks was 20.2 percent with tirzepatide against 13.7 percent with semaglutide — a 47 percent relative difference — and 31.6 percent of tirzepatide-treated participants achieved at least twenty-five percent weight loss against sixteen percent on semaglutide[9].
What are the most common adverse events reported with tirzepatide in research?
Gastrointestinal events — nausea, diarrhoea, vomiting, and constipation — are the most common adverse events across the trial programme. They are dose-dependent and concentrated during the titration period; most are mild to moderate, and gastrointestinal-related discontinuation is the leading reason participants leave trials[17]. Acute pancreatitis has been reported as a rare event without clear dose dependence. A boxed warning in the FDA label addresses the risk of thyroid C-cell tumours, derived from rodent two-year carcinogenicity studies; the human relevance has not been confirmed, but the label-stated contraindication in subjects with a personal or family history of medullary thyroid carcinoma or MEN-2 syndrome is unambiguous.
Has tirzepatide been studied for heart failure or sleep apnoea?
Yes. SUMMIT enrolled adults with heart failure with preserved ejection fraction and obesity and reported a thirty-eight percent relative reduction in the composite of cardiovascular death or worsening heart failure over a median two years on up to fifteen milligrams once weekly, with measurable reductions in left-ventricular mass and paracardiac adipose tissue[6]. SURMOUNT-OSA enrolled adults with moderate-to-severe obstructive sleep apnoea and obesity and reported reductions in apnoea-hypopnoea index of approximately twenty-five to twenty-nine events per hour at ten or fifteen milligrams against roughly five events per hour with placebo at fifty-two weeks, across both PAP-using and non-PAP cohorts[7].
What is the molecular structure of tirzepatide?
Tirzepatide is a thirty-nine-residue linear peptide conjugated to a C20 fatty diacid moiety via a γ-glutamate linker at lysine position twenty. It carries two α-aminoisobutyric acid (Aib) substitutions, at positions two and thirteen, which resist proteolytic cleavage by DPP-4 and other proteases. The C-terminus is amidated. Secondary structure is predominantly α-helical, and in solution the molecule exists in a monomer-trimer-hexamer equilibrium. Cryo-electron-microscopy work has shown that the molecule engages the GIP receptor in a fully active conformation and adopts a distinct binding mode at the GLP-1 receptor, supporting biased signalling[13].
Why is tirzepatide given as a once-weekly subcutaneous injection?
The once-weekly cadence is a direct consequence of the pharmacokinetic profile. The mean elimination half-life of approximately five days, together with subcutaneous bioavailability of approximately eighty percent and ninety-nine-percent albumin binding, supports a dosing interval that is comparable to several elimination half-lives — long enough to permit steady-state at approximately four weeks of weekly dosing, short enough to keep peak-to-trough variation within a tolerable range[5]. The structural features that produce the extended half-life — the C20 fatty diacid moiety and the Aib substitutions — were specifically engineered for once-weekly compatibility.
What is the difference between MASH resolution and fibrosis improvement in SYNERGY-NASH?
In SYNERGY-NASH, the primary endpoint was resolution of metabolic dysfunction-associated steatohepatitis (MASH) without worsening of fibrosis — that is, the disappearance of the steatohepatitis histological pattern on liver biopsy while fibrosis stage did not increase. The secondary endpoint was fibrosis improvement of at least one stage without worsening of MASH. The primary endpoint was met at all three doses: 51.8, 62.8, and 73.3 percent on five, ten, and fifteen milligrams achieved MASH resolution without fibrosis worsening at fifty-two weeks against 13.2 percent on placebo[8]. The two endpoints measure related but distinct histological outcomes; resolution speaks to the active steatohepatitis pattern, while fibrosis improvement speaks to the scarring stage.
Has tirzepatide been studied for kidney outcomes?
Yes, in a post-hoc analysis of SURPASS-4. Over a median follow-up of eighty-five to one hundred and four weeks, tirzepatide nearly halved the risk of a composite kidney endpoint — eGFR decline of at least forty percent, renal death, kidney failure, or new macroalbuminuria — against insulin glargine, with reduced urine albumin-to-creatinine ratio and an approximately two-millilitre-per-minute-per-1.73-square-metre-per-year slower eGFR decline[10]. A pooled post-hoc analysis of SURPASS-1 through 5 separately observed clinically meaningful reductions in urine albumin-to-creatinine ratio across participants with type 2 diabetes, including those with chronic kidney disease[18].
Does tirzepatide affect blood pressure?
A pooled analysis of SURPASS-1 through 5 reported reductions in systolic blood pressure of approximately 4.2 to 5.8 millimetres of mercury, dose-dependently, in adults with type 2 diabetes on five, ten, and fifteen milligrams subcutaneous once weekly. The reductions were independent of background antihypertensive use[11]. SURMOUNT-OSA additionally reported systolic-blood-pressure reductions alongside its apnoea-hypopnoea findings[7]. The blood-pressure effect appears to operate independently of weight reduction, though the two are clinically correlated.
What does "research peptide" mean in the context of tirzepatide?
The phrase has two meanings that should not be conflated. In one sense, tirzepatide is a peptide that is studied in research — the SURPASS, SURMOUNT, SUMMIT, SURMOUNT-OSA, and SYNERGY-NASH programmes are the published expression of that research, and the molecule has received FDA approval for type 2 diabetes and for chronic weight management. In another sense, the term "research peptide" is sometimes used by online vendors to describe non-pharmaceutical-grade material sold ostensibly for laboratory use; that material has not been characterised for identity, purity, or sterility and is not equivalent to the pharmaceutical product. Get Tirzepatide does not sell either form.
What is the WADA status of tirzepatide?
Tirzepatide, as a peptide hormone receptor agonist, falls under the World Anti-Doping Agency Prohibited List section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Athletes subject to WADA testing should consult current guidance for the exact status of any peptide hormone receptor agonist in the current Prohibited List. Get Tirzepatide does not provide doping-control advice.
What is this site, exactly?
Get Tirzepatide is an independent editorial project that publishes summaries of the peer-reviewed research literature on tirzepatide. It is not a clinic. It does not employ clinicians, prescribers, or pharmacists. It does not manufacture, sell, or distribute any product. Its only work is editorial commentary on publicly available science. The "get" in the domain name refers to the editorial framing of the project — getting the full record laid out with ceremony — and is not a claim about the site's services.